CSI Market
Sign In | Register

Bio rad Laboratories Inc (BIO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access BIO quarterly Cash Flow →
The quarterly cash flow data below helps track how Bio rad Laboratories Inc's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income0.00
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Paymentsforproceedsfromderivativeinstrumentsoperatingactivities-38.10
Income taxes0.00
Gain (Loss) on Sale of Securities, Net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Other Operating Liabilities0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Deferred Income Taxes0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities570.30
Discontinued operations0.00
Net Cash flow from Operating Activities532.20
Investing Activities
Capital Expenditures-157.60
Sale of Capital Items0.10
Short-term Investments Proceeds855.60
Short-term Investments Acq.0.00
Payments for (Proceeds from) Derivative Instrument, Investing Activities0.00
Payments For Acquisitions Net Of Cash Received And Long Term Investments-
Purchases Of Marketable Securities And Investments-
Payments to Acquire Restricted Investments0.00
Payments to Acquire Loans Held-for-investment0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-669.30
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments for Previous Acquisition-218.50
Interest in Subsidiaries and Affiliates0.00
Proceeds from Divestiture of Businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-189.70
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-0.50
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-279.70
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-492.80
Net Borrowings Payments On Line Of Credit Arrangements And Notes Payable-
Paymentsofcontingentconsideration-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents489.80
Option Premium Proceeds For Structured Purchases Of Treasury Stock-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-283.20
Effect of exchange rate on cash flow-16.90
Discontinued operations0.00
Free Cash Flow374.70
Total Cash Flow42.40
4 historic quarters locked

Sign in to unlock the full Bio rad Laboratories Inc cash flow history.

Sign In Create Free Account

About Bio rad Laboratories Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 12, 2026
  • Source: bio-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000012208-26-000010

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License